Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of BCX7353 to Prevent Angioedema Attacks in Subjects With Hereditary Angioedema

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Key Inclusion Criteria:~* A clinical diagnosis of HAE type I or II~* Documented HAE attacks within a defined calendar period~* Access to acute attack medications~* Sexually active women of child-bearing potential and sexually active men must utilize effective contraception~Key Exclusion Criteria:~* Women who are pregnant or breast-feeding~* Any clinical condition or medical history that would interfere with the subject's safety or ability to participate in the study~* Use of C1INH, androgens or tranexamic acid for prophylaxis of HAE attacks~* History of or current alcohol or drug abuse~* Infection with hepatitis B, hepatitis C or HIV~* Participation in any other investigational drug study currently or within the last 30 days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Part 1: BCX7353 350 mg once daily (Type: EXPERIMENTAL): BCX7353 capsules, 350 mg dose administered once per day for 28 days
- Parts 2 and 3: BCX7353 250 mg once daily (Type: EXPERIMENTAL): BCX7353 capsules, 250 mg dose administered once per day for 28 days
- Parts 2 and 3: BCX7353 125 mg once daily (Type: EXPERIMENTAL): BCX7353 capsules, 125 mg dose administered once per day for 28 days
- Parts 1, 2 and 3: Placebo (Type: PLACEBO_COMPARATOR): Placebo capsules, administered once per day for 28 days
- Part 3: BCX7353 62.5 mg once daily (Type: EXPERIMENTAL): BCX7353 capsules, 62.5 mg dose administered once per day for 28 days

Based on this trial design, predict the completion outcome and termination type (if applicable).